Trevena Q4 2019 Earnings Report
Key Takeaways
Trevena reported a net loss attributable to common stockholders of $6.4 million, or $0.07 per share, for the fourth quarter of 2019. The company's cash, cash equivalents, and marketable securities were $35.8 million at December 31, 2019.
FDA acknowledged receipt of the resubmitted NDA for IV Oliceridine with a PDUFA goal date set for August 7, 2020.
Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder (TRV734).
Announced NIH collaboration to evaluate TRV045 for epilepsy.
Updated guidance on extended cash runway, funding operations into Q1 2021.
Trevena
Trevena
Forward Guidance
Trevena believes that its cash and cash equivalents and marketable securities as of December 31, 2019, together with interest thereon, to be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the first quarter of 2021.